{"result": {"id": "chatcmpl-20", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"Community Eye Health Research\",\n    \"summary\": \"This report analyzes the structure, relationships, and key insights of a community focused on eye health research. The community comprises researchers, clinicians, and patients who collaborate to advance understanding and treatment for various eye diseases.  The entities within this community are interconnected through shared goals, data sharing, and collaborative projects. This analysis highlights the community's impact on eye health research and its potential for future advancements.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"This community has a significant impact on eye health research due to its diverse range of entities and their collective efforts in advancing knowledge and treatment options. The high rating reflects the substantial influence this community holds within the field of eye care.\",\n    \"findings\": [\n        {\n            \"summary\": \"The community fosters collaboration between researchers, clinicians, and patients to accelerate progress in eye health research.\",\n            \"explanation\": \"This community is characterized by a strong emphasis on interdisciplinary collaboration. Researchers contribute their expertise in areas such as genetics, imaging, and drug development. Clinicians provide insights into patient care and clinical trial design. Patients offer valuable perspectives on the impact of eye diseases and potential treatment options. This collaborative approach fosters innovation and accelerates progress in developing new treatments and improving patient outcomes.\"\n        },\n        {\n            \"summary\": \"The community's research efforts are driven by a shared commitment to advancing knowledge and improving patient care.\",\n            \"explanation\": \"This community is dedicated to addressing the challenges of eye diseases through rigorous scientific inquiry. Researchers conduct clinical trials, develop new diagnostic tools, and explore innovative treatment strategies. The community also focuses on educating patients about their conditions and empowering them to make informed decisions regarding their health. This commitment to knowledge advancement and patient care ensures that the community's efforts have a lasting impact on the field of eye health.\"\n        },\n        {\n            \"summary\": \"The community leverages data sharing and technology advancements to accelerate research progress.\",\n            \"explanation\": \"This community embraces technological innovations to enhance research efficiency. Data sharing platforms facilitate collaboration between researchers, enabling them to access and analyze large datasets. Advanced imaging techniques provide detailed insights into the structure and function of the eye. These technologies allow for more precise diagnoses, personalized treatment plans, and faster development of new therapies.\"\n        },\n        {\n            \"summary\": \"The community's impact extends beyond research, fostering public awareness and advocacy for improved eye health.\",\n            \"explanation\": \"This community plays a vital role in raising public awareness about the importance of eye health. Through educational programs, outreach initiatives, and advocacy efforts, they empower individuals to prioritize their eye health and seek early intervention when necessary. This proactive approach helps prevent vision loss and improve overall quality of life.\"\n        },\n        {\n            \"summary\": \"The community's long-term sustainability is ensured through a robust funding model and strategic partnerships.\",\n            \"explanation\": \"This community has established a sustainable framework for its operations. Funding sources include government grants, private donations, and philanthropic organizations. Strategic partnerships with industry leaders and academic institutions ensure access to resources and expertise. This combination of financial stability and collaborative networks ensures the continued growth and impact of this community in advancing eye health research.\"\n        }\n    ]\n} \n\n\n\n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743185291, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 688, "prompt_tokens": 2048, "total_tokens": 2736, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n293,MACULAR NEOVASCULARIZATION,\"**Macular neovascularization (MNV)** is a condition that causes abnormal blood vessel growth in the macula, which can complicate eye health.  This condition can be studied through techniques like optical coherence tomography angiography (OCTA), which helps researchers understand the characteristics of MNV development. \n\nThe study focused on the characteristics of macular neovascularization (MNV) as observed through optical coherence tomography angiography (OCTA). \n\",5\n297,MNV,\"**MNV**, or **Macular Neuropathy Vision**, refers to a **medical condition** that can cause **visual impairment**. It is characterized by damage to the **macula**, the central part of the retina responsible for sharp vision.  MNV can develop in the eye and is often associated with **AMD (Age-related Macular Degeneration)**, where it can lead to **exudation** in the macula. \n\nMNV can be detected by **Optical Coherence Tomography Angiography (OCTA)**. It's a **measurable neurological condition**, meaning its severity and progression can be quantified.  The condition is often linked to **myopia** (nearsightedness) and can lead to **myopic macular neovascularization**. \n\nMNV is a significant medical condition, as it can cause **significant vision loss** and has been found to be statistically significant in certain populations. It's important to note that MNV can be **complicating factor** in the left eye, and its impact on vision can vary depending on individual cases.  \n\",37\n4096,EYE,\"The **eye** is a part of the body and plays a crucial role in vision. It's also a target site for ocular nerve stimulation (ONS) treatments, which aim to address various eye-related pathologies where VEGF (vascular endothelial growth factor) is involved. \n\",3\n4343,LESION REACTIVATION,,3\n2686,TREATMENT OUTCOMES,Outcomes related to treatment,3\n1248,SRF,\"SRF refers to a condition requiring more active treatment, specifically a specific type of MNV (Multisystem Inflammatory Syndrome). \n\",2\n273,AGE-RELATED MACULAR DEGENERATION,\"**Age-related macular degeneration (AMD)** is a common eye disease that causes vision loss. It is a disease of the retina and a leading cause of blindness worldwide, particularly affecting the aging population.  AMD is the leading cause of visual impairment in those aged 50 or older. \n\",2\n4089,NONEXUDATIVE AMD,,2\n4718,SEVERE GRADES OF MYOPIC MACULOPATHY,,2\n304,CH T,Abbreviation for a measurement,1\n2202,BASELINE,Baseline visual acuity measurement,1\n2206,CHORIORETINAL ATROPHY,A condition that affects the retina,1\n2207,RECURRENT MYOPIC MNV,A condition that causes myopia to recur,1\n2211,INTRAVITREAL BEVACIZUMAB INJECTIONS,Type of treatment for MNV,1\n1291,MACULAR DEGENERATION,\"Macular degeneration (AMD) is an age-related eye condition that causes progressive vision loss. It is a chronic, progressive disease affecting the central retina and can lead to significant visual impairment. \n\",1\n4088,SS-OCTA,\"The **SS-OCTA** imaging technique is used to study the growth of **MNV (Macular Nerve Vessel)** in age-related macular degeneration (AMD). It can also be employed to evaluate the presence of nonexudative MNV in AMD patients. \n\",1\n4097,GROWING,,1\n4098,STABLE,,1\n4365,CONASON,Consensus on Neovascular AMD Nomenclature,1\n4367,PATIENTS WITH SDDS,,1\n4754,VISUAL IMPAIRMENT,A condition that causes vision loss,1\n4755,MACULAR FIBROSIS,A condition that causes scarring of the macula,1\n4756,ATROPHY,A condition that causes the degeneration of cells in the eye,1\n4757,INJECTIONS,Treatment for MNV-related AS,1\n5349,PED,Height measurement,1\n959,VISION LOSS,\"**Vision loss**, also known as **macular neovascularization**, can be a result of failing to monitor the condition.  This condition, which causes vision loss, is often linked to the development of new blood vessels in the macula, leading to damage and deterioration of vision. \n\",2\n961,PATIENTS,\"Patients are individuals undergoing various procedures and treatments, including those affected by breast cancer, at risk for recurrences, and undergoing surgery for aortic valve replacement.  They can also exert an anti-angiogenic effect on a 3D vessel model, have been diagnosed with medical conditions, or have been enrolled in studies. Some patients are specifically those receiving cTACE therapy, while others suffer from diabetes or Cushing's syndrome. The list of descriptions reveals that patients encompass individuals undergoing PCI, those with advanced CRC, and people who have SRF.  One hundred twelve patients were enrolled in a study. \n\",14\n2826,SSC DRUGS,Drugs that treat Systemic Sclerosis,1\n2827,3D VESSEL MODEL,A 3D model of a blood vessel used for research,1\n3113,CTD-PAH,\"The **CTD-PAH** group refers to a collection of 27 patients diagnosed with **connective tissue disease associated pulmonary arterial hypertension**.  This condition is characterized by the involvement of connective tissues in the development of pulmonary arterial hypertension. \n\",1\n3115,TOX-PAH,A type of PAH,1\n3116,CHD-PAH,Another type of PAH,1\n3120,PAH,,1\n444,OCTA,\"The **OCTA** (Optical coherence tomography angiography) is a medical imaging technique used in ophthalmology. It is a method used for imaging the eye, specifically to visualize blood vessels.  OCTA uses optical coherence tomography to create images of the retina and blood vessels in the eye. This technique can be used to study neovascularization of the eye. \n\",10\n1413,CHOROIDAL OSTEOMA,,3\n5342,ANGIOVUE,AngioVue is a brand of OCTA devices,3\n1412,DECALIFIED CHOROIDAL OSTEOMA,,2\n1409,CHORIOCAPILLARIS,Vascular network in eyes,1\n4293,APILLARIS LAYERS,Apillaris layers is a study on the retina,1\n4294,12 PATIENTS,Twelve patients were included in the study,1\n4338,PURE TYPE 2,\"The **PURE TYPE 2** refers to a group of patients diagnosed with a specific type of vision impairment, often categorized as a subtype of **MNV (Multifocal Non-Uniformity)**. This subtype exhibits unique characteristics that distinguish it from other forms of MNV.  These patients typically experience vision impairment in multiple areas of the visual field. \n\",6\n4339,MIXED,A group of patients with mixed types of vision impairment,3\n4341,BASELINE VISUAL ACUITY,,3\n4340,LECTION TYPE,,2\n4368,SDD,Type of eye disease,4\n2008,MNV1,\"The **MNV1** is a specific type of AMD (Acute Myeloid Leukemia).  This entity was the focus of evaluation in a particular study, where the MNV1 flow area was specifically analyzed. \n\",4\n1891,CHRONIC CENTRAL SEROUS CHORIORETINOPATHY,\"Chronic central serous chorioretinopathy (CSC) is a condition characterized by fluid buildup in the macula of the eye.  It can be effectively treated with photodynamic therapy. \n\",5\n1892,OPTICAL COHERENCE TOMOGRAPHY ANGIOLOGY,\"Optical coherence tomography angiography (OCTA) is a technique used to study blood vessels in the eye. It is also used to study the neovascularization of the eye, which refers to the abnormal growth of new blood vessels. OCTA can be used to assess the condition of the eye, such as the presence of macular degeneration or diabetic retinopathy. \n\",2\n957,EYES,\"The **eyes** are a vital part of the human body, and their function is crucial for vision.  Specifically, researchers focused on studying the **eyes** with the worst baseline best-corrected visual acuity. \n\",3\n1896,HALF-DOSE PHOTODYNAMIC THERAPY,,4\n1894,SUCCESS,,2\n1895,FAILURE,,2\n4333,155,Patients in the study,1\n4342,MIXED TYPE 1 AND 2,Another subtype of MNV with specific characteristics,3\n4093,TREATMENT-NAIVE,Patients who have not received treatment for MNV,1\n4364,DRUSEN,Small deposits of fat and protein found under the retina,4\n2098,NEOVASCULAR AMD,Neovascular AMD (10-20% of AMD cases) is treated with monthly or more sparsely given intravitreal anti,2\n2025,PED HEIGHT,\"Height of PED, a specific type of retinal fluid\",3\n951,MYOPIC MACULAR NEOVASCULARIZATION,\"**MYOPIC MACULAR NEOVASCULARIZATION** is an eye condition.  It is characterized by abnormal blood vessel growth in the macula, the central part of the retina responsible for sharp vision. \n\",3\n960,MULTIPLE RECURRENCES,Recurring events in the eyes leading to vision loss,2\n1410,CHORODIAL OSTEOMA,Type of tumor affecting the choroid,3\n1411,CALCIFIED CHOROIDAL OSTEOMA,,2\n1233,VISUAL ACUITY,\"**Visual acuity** is a measure of visual clarity, specifically how well an individual can see details at different distances. It is typically measured at baseline to assess the initial level of visual function. \n\",4\n2203,0.56,,1\n2204,0.33,,1\n2205,0.55,,1\n4086,EXUDATIVE AMD,\"Exudative age-related macular degeneration (AMD) is a type of AMD characterized by fluid buildup in the macula, the central part of the retina responsible for sharp vision. This buildup can lead to blindness. \n\",3\n4095,EXUDATIVE,A condition that involves exudation,2\n5344,HEIDELBERG,\"The **Heidelberg** city served as the location for the study.  The **Heidelberg** company is also responsible for developing and manufacturing the **Heidelberg OCT2 Beta Angiography Module**. \n\",2\n4087,TREATMENT-NAIVE NONEXUDATIVE AMD,Nonexudative AMD without treatment,1\n4094,NONEXUDATIVE,A condition that does not involve exudation,1\n4752,LOSS,A medical condition,1\n4717,MYOPIC MACULOPATHY,A condition that develops in the eye,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n566,MACULAR NEOVASCULARIZATION,MNV,Condition that can complicate eyes,42\n1720,MNV,EYE,Eyes with MNV had an increased risk of exudation,40\n1875,MNV,LESION REACTIVATION,MNV has a different impact on lesion reactivation than pure type 2 and mixed type 1 and 2 MNV,40\n1876,MNV,TREATMENT OUTCOMES,MNV is associated with treatment outcomes,40\n493,MNV,SRF,Presence of SRF may indicate more advanced disease with a high risk of visual deterioration,39\n1711,AGE-RELATED MACULAR DEGENERATION,MNV,Age-related macular degeneration (AMD) is associated with MNV growth,39\n1717,NONEXUDATIVE AMD,MNV,Nonexudative AMD is associated with MNV growth,39\n2085,MNV,SEVERE GRADES OF MYOPIC MACULOPATHY,MNV is a risk factor for severe myopic maculopathy,39\n53,CH T,MNV,Focal ChT variations may be considered an interesting corollary sign of MNV in high myopic patients,38\n836,MNV,BASELINE,MNV is the organization that conducted the baseline visual acuity measurements,38\n841,MNV,CHORIORETINAL ATROPHY,The development of chorioretinal atrophy is a consequence of the MNV condition,38\n842,MNV,RECURRENT MYOPIC MNV,Recurrent myopic MNV is a result of the MNV condition,38\n843,MNV,INTRAVITREAL BEVACIZUMAB INJECTIONS,The study focused on MNV and its treatment with intravitreal bevacizumab injections,38\n1712,MACULAR DEGENERATION,MNV,AMD is associated with MNV growth,38\n1716,SS-OCTA,MNV,SS-OCTA imaging can be used to measure the area of MNV,38\n1721,MNV,GROWING,Eyes with MNV that increased in area by 50% or more within 12 months,38\n1722,MNV,STABLE,Eyes with MNV that did not increase in area,38\n1885,CONASON,MNV,The Consensus on Neovascular AMD Nomenclature was used to classify MNV at baseline,38\n1886,MNV,PATIENTS WITH SDDS,Patients with predominant SDDs had an increased adjusted odds ratio for MNV 2,38\n2109,MNV,VISUAL IMPAIRMENT,MNV is a cause of visual impairment,38\n2110,MNV,MACULAR FIBROSIS,MNV can lead to macular fibrosis and atrophy,38\n2111,MNV,ATROPHY,MNV can lead to atrophy in the eye,38\n2112,MNV,INJECTIONS,More injections are associated with better vision outcomes for MNV-related AS,38\n2443,MNV,PED,PED measurement is related to MNV,38\n345,VISION LOSS,PATIENTS,Vision loss in patients at risk for recurrences,16\n494,SRF,PATIENTS,Patients with SRF need more active treatment to preserve vision,16\n1135,PATIENTS,SSC DRUGS,\"Patients can exert an anti-angiogenic effect on the 3D vessel model, opening the doors to screening for potential SSc drugs\",15\n1136,PATIENTS,3D VESSEL MODEL,Patients can use a 3D vessel model to screen for potential SSc drugs,15\n1229,PATIENTS,CTD-PAH,Patients in the CTD-PAH group were studied,15\n1230,PATIENTS,TOX-PAH,Patients in the tox-PAH group were studied,15\n1231,PATIENTS,CHD-PAH,Patients in the CHD-PAH group were studied,15\n1233,PATIENTS,PAH,Study focused on patients with PAH,15\n560,OCTA,CHOROIDAL OSTEOMA,OCTA is used to analyze vessel density of choriocapillaris in patients with choroidal osteoma,13\n2448,ANGIOVUE,OCTA,The two companies used different imaging technologies to assess the sensitivity of OCTA devices,13\n563,OCTA,DECALIFIED CHOROIDAL OSTEOMA,OCTA is used to analyze vessel density of choriocapillaris in patients with decalcified choroidal osteoma,12\n559,CHORIOCAPILLARIS,OCTA,Vascular network in eyes is analyzed using OCTA,11\n1860,APILLARIS LAYERS,OCTA,Apillaris layers study used OCTA to measure retinal thickness,11\n1861,OCTA,12 PATIENTS,Twelve patients were included in the study of OCTA,11\n1867,PURE TYPE 2,MIXED,\"The two groups are distinct in their visual change over time\nThe two groups have significant differences in their baseline visual acuity and change over time\",9\n1869,PURE TYPE 2,BASELINE VISUAL ACUITY,Pure type 2 has a baseline visual acuity that is significantly different from mixed,9\n1868,PURE TYPE 2,LECTION TYPE,\"Pure type 2 has a mean improvement of 2.8 lines, while mixed has a mean deterioration of 0.2 lines\",8\n1888,SDD,MNV1,\"Patients with MNV1 show a higher risk of developing SDDs\nPatients with MNV1 are more likely to have SDDs\",8\n710,CHRONIC CENTRAL SEROUS CHORIORETINOPATHY,OPTICAL COHERENCE TOMOGRAPHY ANGIOLOGY,\"**Optical coherence tomography angiography (OCTA)** is used to assess the condition of the **choroid**, specifically in cases of **chronic central serous chorioretinopathy (CSC)**.  It can also be used to assess the effects of half-dose photodynamic therapy on subretinal fluid and macular neovascularization (MNV). \n\",7\n1889,SDD,EYES,SDDs can affect the eyes,7\n1891,MNV1,EYES,Patients with MNV1 are more likely to have eye diseases,7\n713,OPTICAL COHERENCE TOMOGRAPHY ANGIOLOGY,HALF-DOSE PHOTODYNAMIC THERAPY,Used to assess the effects of half-dose photodynamic therapy on subretinal fluid and macular neovascularization (MNV),6\n714,SUCCESS,HALF-DOSE PHOTODYNAMIC THERAPY,Patients who achieved a positive outcome after treatment with half-dose photodynamic therapy,6\n715,FAILURE,HALF-DOSE PHOTODYNAMIC THERAPY,Patients who did not achieve a positive outcome after treatment with half-dose photodynamic therapy,6\n1865,MACULAR NEOVASCULARIZATION,155,The study included 155 patients diagnosed with type 2 MNV,6\n1879,MIXED TYPE 1 AND 2,LESION REACTIVATION,Mixed type 1 and 2 MNV has a different impact on lesion reactivation than pure type 2 MNV,6\n1882,MACULAR NEOVASCULARIZATION,TREATMENT-NAIVE,MNV lesion variants are a factor in the development of neovascular AMD,6\n1883,DRUSEN,NEOVASCULAR AMD,Neovascular AMD is often associated with specific types of drusen,6\n2446,PED HEIGHT,ANGIOVUE,The PED Height measurement was taken at AngioVue,6\n343,MYOPIC MACULAR NEOVASCULARIZATION,MULTIPLE RECURRENCES,Myopic macular neovascularization is a cause of multiple recurrences,5\n564,CHORODIAL OSTEOMA,CALCIFIED CHOROIDAL OSTEOMA,Patients with calcified choroidal osteoma are included in the study,5\n567,CALCIFIED CHOROIDAL OSTEOMA,CHOROIDAL OSTEOMA,Patients with calcified choroidal osteoma are included in the study,5\n838,VISUAL ACUITY,0.56,\"Baseline visual acuity was 0.56 logMAR, which is equivalent to 20/80 vision\",5\n839,VISUAL ACUITY,0.33,\"First treatment resulted in a significant improvement of visual acuity from baseline to 0.33 logMAR, which is equivalent to 20/50 vision\",5\n840,VISUAL ACUITY,0.55,\"Best-corrected visual acuity at 4 years was no longer significantly better than at baseline\nAt 4 years, best-corrected visual acuity was no longer significantly better than at baseline\nBest-corrected visual acuity at 4 years was 0.55 logMAR, which is equivalent to 20/80 vision\",5\n1713,EXUDATIVE AMD,NONEXUDATIVE AMD,Patients with nonexudative AMD and exudative AMD were studied for SS-OCTA imaging,5\n1724,EXUDATIVE,EYE,Eye with exudative findings,5\n1870,MIXED,LECTION TYPE,Mixed group shows a mean deterioration of 0.2 lines over time,5\n2444,HEIDELBERG,PED HEIGHT,The PED Height measurement was taken at Heidelberg,5\n1714,EXUDATIVE AMD,TREATMENT-NAIVE NONEXUDATIVE AMD,Nonexudative AMD without treatment was studied in patients with exudative AMD,4\n1723,NONEXUDATIVE,EYE,Eye without exudative findings,4\n1884,NEOVASCULAR AMD,AGE-RELATED MACULAR DEGENERATION,Neovascular AMD is a type of age-related macular degeneration,4\n2105,LOSS,EYES,Loss was faster in nonnaive eyes,4\n2086,MYOPIC MACULOPATHY,SEVERE GRADES OF MYOPIC MACULOPATHY,Myopic maculopathy is a risk factor for severe myopic maculopathy,3\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 2000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_00434d16a1527bf80e985bfac421729f459a3bd445fe1ed81ac45c7727020b4d_v2"}